Lilly weight-loss drug shows promise as a sleep apnea treatment
Indianapolis-based Eli Lilly and Co. says its popular weight-loss treatment Zepbound showed potential to treat patients with obstructive sleep apnea in two late-stage clinical trials. Lilly shares rose 0.5%, to close at $750.77 each, after the announcement.... Read More